{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-196459","form_type":"8-K","ticker":"VERU","cik":"0000863894","company_name":"VERU INC.","filed_at":"2024-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:16.072294+00:00","generated_at":"2026-05-31T11:27:33.195631+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Veru Q3 net rev $4.0M, net loss $0.07; Phase 2b QUALITY study fully enrolled (>150 pts), topline Jan 2025","bullets":["Q3 net revenue $4.0M (up 21% YoY); operating loss $10.9M vs $13.7M.","Net loss $11.0M ($0.07/sh) vs $12.5M ($0.14/sh) prior year.","Phase 2b QUALITY trial full enrollment >150 patients achieved; topline lean body mass data expected Jan 2025.","Cash $29.2M at June 30, 2024 vs $9.6M at Sept 30, 2023.","Enobosarm aims to preserve muscle during GLP-1 weight loss; extension study data expected Q2 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-196459","json":"https://secwatch.observer/filing/0001193125-24-196459.json","markdown":"https://secwatch.observer/filing/0001193125-24-196459.md","text":"https://secwatch.observer/filing/0001193125-24-196459.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/863894/000119312524196459/0001193125-24-196459-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/863894/000119312524196459/d877606d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T11:27:33.195631+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}